Abstract
Botulinum toxin A (BTX) treatment in patients with neurogenic bladder dysfunction is known to be an effective therapy option. Several studies showed that its pharmacological effects significantly reduce detrusor muscle overactivity. But, modulation of neuromuscular transmission might also result in urinary retention, an adverse event why BTX treatment in Parkinson's patients is still under debate.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
